Navigation Links
DaVita Releases Top Clinical Priorities for 2009
Date:2/23/2009

Over 500 Nephrologists Gathered in Phoenix to Focus on Catheter Reduction and Reduction in First-Year Mortality Rates in Hemodialysis Patients

EL SEGUNDO, Calif., Feb 23 /PRNewswire-FirstCall/ -- DaVita Inc., a leading provider of kidney care services, unveiled its 2009 Clinical Priorities to its partnering nephrologists during the Annual Physicians Leadership Meeting in Phoenix, one of the largest gatherings of nephrologists of the year. Continuing DaVita's "Relentless Pursuit of Quality," DaVita Chief Medical Officer, Allen R. Nissenson, MD and his team highlighted DaVita's 2009 Key Clinical Initiatives and provided physician leaders the latest information on industry trends, clinical practices, and business tools to continue to provide superior quality patient care. DaVita treats 1-in-4 dialysis patients in America and is a leader in superior clinical outcomes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

Amongst the top ten clinical initiatives announced, DaVita outlined the top two priorities for physician partners: striving for reduction of first-year mortality rates and reducing catheter use. DaVita will continue the success of the CathAway program, in which the entire care team educates and organizes the patients' catheter removal plan. DaVita will also work to lead the entire renal community to decrease first-year mortality in dialysis patients. These two priorities, in conjunction with DaVita's enhanced clinical programs, are just some of the ways partnering physicians can work to transform kidney care across America. A few of the other highlighted programs include:

  • IMPACT(TM) - A comprehensive patient management effort designed to focus on the first three months of dialysis and to improve the key indicators associated with lower morbidity and mortality.'/>"/>

SOURCE DaVita Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. DaVita Receives Civil Complaint
2. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
3. DaVita Teammates Bicycling 230 Miles for Kidney Disease Education
4. DaVita Volunteers Raise More than $1,000,000 for Nationwide Kidney Education and Prevention Programs
5. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
6. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
7. DaVita Nurse Gives Keynote Speech to St. Georges Hospital Vascular Access Annual Meeting in London
8. DaVita Inc. to Present at JPMorgan Healthcare Conference
9. DaVita and Phoenix-Based Southwest Kidney Institute Form Broad Partnership
10. Nations Leading Dialysis Provider - DaVita - Partners with eDiets(R) to Launch One-of-a-Kind Diet Helper Online Nutrition and Meal Planning Tool for Late-Stage Kidney Disease Patients and Caregivers
11. DaVita Announces Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Today, Zane Benefits, the #1 ... a new eBook, Affordable Care Act 101. , ... feel uncertain about how the ACA impacts their ... line. , The new eBook outlines key ACA ... their upcoming health insurance decisions. , Read the ...
(Date:8/20/2014)... Locating rates for insurance packages will now be an ... new source of term life insurance providers has been added ... 50 states at http://quotespros.com/life-insurance.html . , The database ... available for the public to find out the exact annual ... quotations that are available are good through the rest of ...
(Date:8/20/2014)... group representing U.S. obstetricians is calling for all pregnant ... the American College of Obstetricians and Gynecologists (ACOG), several ... and effectiveness of flu vaccination during pregnancy. "The ... dangerous to pregnant women, as it can cause pneumonia, ... of the college,s Immunization Expert Work Group, explained in ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... a group of rhesus monkeys from deadly Marburg virus, a ... 90 percent of those it infects, researchers report. The ... virus, even when it was given three days after infection, ... Science Translational Medicine . This is the first ...
(Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Price Database Now Helps Quote Prices for Adults in 50 States Online 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Patient perspectives on breast reconstruction following mastectomy 2
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the Campaign,for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
... March 27 The Richard B. and,Lynne V. ... John Ray have joined the Institute,s Board of ... for the Institute., "Mary Matalin,s experience in ... to the Institute as we build our organization ...
... Calif., March 27 Clarient, Inc.,(Nasdaq: CLRT ), ... the pharmaceutical industry, today announced,that it is scheduled to ... Co.,9th Annual Las Vegas Investor Conference at 4:00 p.m. ... conference is being held at the Palms,Casino Resort April ...
... Now Have Choices and Flexibility ... Typically Available on Larger Plans, NEW YORK, ... to,nine employees can now choose from a wider selection of ... larger,companies., The Guardian Life Insurance Company of America (Guardian), ...
... a mental rigidity that keeps them from folding their ... form of mental rigidity that leads to compulsive behavior ... luck even when they,re on a losing streak, a ... causes compulsive gambling, but it,s been suggested that environmental ...
... CHICAGO, IL MARCH 27, 2008 The Cardiovascular ... meta-analysis to date comparing mortality rates for drug-eluting stents ... Stent Revolution VII meeting tomorrow evening in Chicago. ... studieswas performed by a team of researchers led by ...
Cached Medicine News:Health News:D.C. Kids 'Kick Butts' on April 2 2Health News:D.C. Kids 'Kick Butts' on April 2 3Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 3Health News:Compulsive Gamblers Don't Learn From Their Mistakes 2Health News:Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use 2
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
Bone Curette, 170 mm...
Bone Currettes...
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
...
Medicine Products: